Vaxxas has received a manufacturing licence from Australia’s Therapeutic Goods Administration (TGA) for its high-density microarray patch (HD-MAP) for clinical studies at a biomedical facility in ...

A recent study highlights how DNA microarray technology enables high-throughput gene analysis, supporting variation detection, expression profiling, and clinical research. By refining probe design and ...

A recent study on DNA microarray technology highlights its essential role in enabling high-throughput analysis of large numbers of genes through arrays of probes integrated on a solid-phase support.

The audio version of this article is generated by AI-based technology. Mispronunciations can occur. We are working with our partners to continually review and improve the results. A file photo shows ...

We may receive commissions from some links to products on this page. Promotions are subject to availability and retailer terms. Today's elevated interest rate environment has also made some annuity ...

The clinical study aims to evaluate a vaccine for avian influenza A (H7N9) delivered by Vaxxas’ high-density microarray patch (HD-MAP), and is funded by the United States government as a potential ...

Jane Kelsey gave evidence (relating to her PhD thesis addressing the development of the 'principles of the Treaty') at the Waitangi Tribunal urgency inquiry on the Treaty Principles Bill. She is a ...

The first study of the use of microarray patches to vaccinate children has shown that the method is safe and induces strong immune responses. The phase 1/2 randomized trial compared results from the ...

Background: Ultraviolet B (UVB) from sunlight represents a major environmental factor that causes toxic effects resulting in structural and functional cutaneous abnormalities in most living organisms.